fda semaglutide warning november 2025 Medscape | The has approved once-daily oral 25 mg (Wegovy Pill, Novo Nordisk) as the first GLP-1 agonist pill for weight management. ⁠ U.S. FDA finds no evidence

Compounded GLP-1 (semaglutide) is a prescription medication that mimics a naturally occurring hormone called glucagon-like peptide-1

Decades of safety data from diabetes trials show GLP-1 agonists are well-tolerated over extended periods

Benefits of Provider Supported Weight Management Effective Weight Loss Significant reduction in body weight, even if other weight loss efforts have failed

This may mean retatrutide is particularly well-suited for: People with severe obesity Individuals aiming for very large weight loss Patients whose health risks are high enough to justify a stronger medication How Retatrutide Fits Into the Competitive Landscape Lilly is aggressively expanding its obesity drug portfolio